Latest Breaking News On - Chronic obstructive pulmonary disorder - Page 12 : comparemela.com

PAO Group, Inc.: PAOG Confirms CBD Nutraceutical Q4 Revenue Plans

PAO Group, Inc.: PAOG Confirms CBD Nutraceutical Q4 Revenue Plans Sandusky, Ohio (Newsfile Corp. - May 11, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed plans to introduce three CBD Nutraceutical Products beginning in the fourth quarter of this year, 2021. On Friday, PAOG released a preview of the company s plan to launch a CBD Nutraceuticals line of products. PAOG s CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.

PAOG Partners With PURA, ALKM and USMJ To Launch CBD Nutraceutical Product Line

PAOG Partners With PURA, ALKM and USMJ To Launch CBD Nutraceutical Product Line News provided by Share this article Share this article SANDUSKY, Ohio, May 7, 2021 /PRNewswire/  PAO Group, Inc. (USOTC: PAOG) today released a preview of the company s plan to launch a CBD Nutraceuticals line of products.  PAOG s CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.

PAO Group, Inc.: PAOG Releases CBD Nutraceutical 2021 Product Launch Preview Highlighting PURA EVERx Partnership, ALKM Co-Packing and USMJ Distribution

(0) Sandusky, Ohio (Newsfile Corp. - May 7, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today released a preview of the company s plan to launch a CBD Nutraceuticals line of products. PAOG s CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT. Starting in the fourth quarter of 2021, PAOG plans to begin the introduction of three CBD Nutraceuticals.

PAOG 2021 CBD Nutraceuticals Sales Plan Preview This Friday To Include ALKM and USMJ Partnership Highlights

PAOG 2021 CBD Nutraceuticals Sales Plan Preview This Friday To Include ALKM and USMJ Partnership Highlights News provided by Share this article Share this article SANDUSKY, Ohio, May 6, 2021 /PRNewswire/ PAO Group, Inc. (USOTC: PAOG) today highlighted that the upcoming CBD Nutraceutical Sales Rollout Presentation scheduled for tomorrow, Friday, May 7, 2021, will feature the roles Alkame Holdings, Inc. (USOTC: ALKM) and North American Cannabis Holdings, Inc. (USOTC: USMJ) play in the CBD Nutraceutical Rollout. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT .

PAOG 2021 CBD Nutraceuticals Rollout Preview This Friday